Overview

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-24

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of Iparomlimab and Tuvonralimab in combination with Lenvatinib and TACE for advanced hepatocellular carcinoma by assessing Progression-Free Survival (PFS).

Phase:

PHASE2

Details

Lead Sponsor:

The Second Affiliated Hospital of Shandong First Medical University